摘要
目的:观察重组人干扰素α-1b注射液佐治小儿手足口病的临床疗效。方法:选取我院2006年1月至2010年5月收治的105例手足口病患儿,按照随机数表法随机分为观察组53例和对照组52例,两组患儿均给予常规治疗,观察组患儿在常规治疗基础上加用重组人干扰素α-1b注射液肌肉注射,剂量范围为6～20μg/d。两组患儿均连续治疗1周为1个疗程,比较临床疗效。结果:(1)观察组总有效率为90.57%,对照组总有效率为78.85%,两组比较差异有统计学意义(χ2=24.154,P<0.01);(2)两组患儿体温恢复时间、皮疹消退时间及总病程比较差异有统计学意义(P<0.01);(3)观察组出现白细胞减少2例,对照组无明显不良反应。结论:重组人干扰素α-1b注射液佐治小儿手足口病疗效显著,但应注意不良反应,根据具体情况适当使用。
Objective： To observe the clinical curative effects of recombinant human interferon α-1b injection in adjuvant treatment of infantile hand-foot-mouth disease. Methods： In Maternal and Child Health Hospital, Jiulongpo District from January 2006 to May 2010, 105 cases of children with hand-foot-mouth disease were randomly divided into an observation group （53 cases） and a control group （52 cases）. The two groups were given conventional treatment. The observation group were in addition treated with recombinant human interferon α-1 b injection intramuscularly, the dose range of 6 -20 μg/d. The two groups were treated continuously for one weeks of one course. A comparison of clinical outcomes was studied. Results： The total effective rate of observation group was 90. 57% ; the total effective rate of control group was 78.85% , the total efficiency were significant different （χ2 = 24. 154, P〈0.01 ）. The temperature recovery times, rash subsided times and total duration in two groups had significant differences （ P〈0.01 ）. （3） Two cases of leucopenia were founded in the observation group; no obvious adverse reaction was observed in the control group. Conclusions： The effect of recombinant human interferon α-1 b injection in adjuvant treatment of infantile hand-foot-mouth disease is ideal, but attention should be paid to the adverse reactions. It should be used appropriately under some specific situations.
出处
《儿科药学杂志》
CAS
2012年第10期22-24,共3页
Journal of Pediatric Pharmacy
关键词
重组人干扰素Α-1B
手足口病
小儿
Recombinant human interferon α-1b
Hand-foot-mouth disease
Infants
